Europe Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.4% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and Rest of Europe) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe acute myeloid leukemia diagnostics market are:

Strategic initiatives by major market players

Increasing awareness of leukemia cancer

Market Players

The key market players in the Europe acute myeloid leukemia diagnostics market are listed below:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Siemens Healthcare GmbH

Merck KGAA

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

BIOMERIEUX

Myriad Genetics, Inc.

Quest Diagnostics Incorporated.

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

Exact Sciences Corporation

Time Medical Holding

PlexBio

MinFound Medical Systems Co., Ltd

Medonica Co. LTD

CANON MEDICAL SYSTEMS CORPORATION

1 INTRODUCTION 53

1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT TYPE LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET END USER COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 75

4.1 PESTEL ANALYSIS 76
4.2 PORTER'S 5 FORCES 77

5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 78

5.1 REGULATORY SCENARIO IN THE U.S. 78
5.2 REGULATORY SCENARIO IN AUSTRALIA 79
5.3 REGULATORY SCENARIO IN JAPAN 79
5.4 REGULATORY SCENARIO IN CHINA 79

6 MARKET OVERVIEW 81

6.1 DRIVERS 83
- 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 83
- 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 85
- 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 85
- 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 86
6.2 RESTRAINTS 87
- 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 87
- 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 87
6.3 OPPORTUNITIES 88
- 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 88
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 88
- 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 89
6.4 CHALLENGES 90
- 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 90
- 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90

7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 91

7.1 OVERVIEW 92
7.2 INSTRUMENTS 95
- 7.2.1 BIOPSY INSTRUMENTS 96
  - 7.2.1.1 BONE MARROW BIOPSY 96
  - 7.2.1.2 NEEDLE BIOPSY 96
  - 7.2.1.3 SURGICAL BIOPSY 96
  - 7.2.1.4 OTHERS 97
- 7.2.2 PATHOLOGY-BASED INSTRUMENTS 97
  - 7.2.2.1 PCR INSTRUMENTS 97
  - 7.2.2.2 SLIDE STAINING SYSTEMS 97
  - 7.2.2.3 TISSUE PROCESSING SYSTEMS 97
  - 7.2.2.4 CELL PROCESSORS 97
  - 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 98
- 7.2.3 IMAGING INSTRUMENTS 98
  - 7.2.3.1 ULTRASOUND SYSTEMS 98
  - 7.2.3.2 CT SYSTEMS 98
  - 7.2.3.3 MRI SYSTEMS 98
  - 7.2.3.4 OTHERS 98
- 7.2.4 OTHERS 98
7.3 CONSUMABLES & ACCESSORIES 99
- 7.3.1 KITS 100
  - 7.3.1.1 PCR KITS 100
  - 7.3.1.2 DNA POLYMERASE KITS 100
  - 7.3.1.3 NUCLEIC ACID ISOLATION KITS 100
  - 7.3.1.4 OTHERS 101
- 7.3.2 REAGENTS 101
  - 7.3.2.1 ASSAYS 101
  - 7.3.2.2 BUFFERS 101
  - 7.3.2.3 PRIMERS 101
  - 7.3.2.4 OTHERS 101
- 7.3.3 PROBES 102
- 7.3.4 OTHER CONSUMABLES 102

8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 103

8.1 OVERVIEW 104
8.2 BLOOD TEST 107
- 8.2.1 COMPLETE BLOOD COUNT (CBC) 108
- 8.2.2 BLOOD CHEMISTRY TESTS 108
- 8.2.3 OTHERS 108
8.3 IMAGING TEST 108
- 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 109
- 8.3.2 MRI 109
- 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 110
- 8.3.4 OTHERS 110
8.4 BONE MARROW TESTS 110
- 8.4.1 BONE MARROW ASPIRATE 111
- 8.4.2 BONE MARROW BIOPSY 111
- 8.4.3 OTHERS 111
8.5 GENETIC TESTS 111
- 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 112
- 8.5.2 KARYOTYPING 112
- 8.5.3 OTHERS 112
8.6 BIOMARKER TEST 112
- 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
- 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
- 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 114
8.7 IMMUNOPHENOTYPING 114
- 8.7.1 FLOW CYTOMETRY 115
- 8.7.2 IMMUNOHISTOCHEMISTRY 115
- 8.7.3 OTHERS 115
8.8 OTHERS 115

9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 117

9.1 OVERVIEW 118
9.2 MYELOBLASTIC (M0) 121
9.3 MYELOBLASTIC (M1) 121
9.4 MYELOBLASTIC (M2) 122
9.5 PROMYELOCYTIC (M3) 123
9.6 MYELOMONOCYTIC (M4) 124
9.7 MONOCYTIC (M5) 124
9.8 ERYTHROLEUKEMIA (M6) 125
9.9 MEGAKARYOCYTIC (M7) 126

10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127

10.1 OVERVIEW 128
10.2 65 AND ABOVE 131
10.3 30-65 131
10.4 BELOW 21 132
10.5 21-29 133

11 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 135

11.1 OVERVIEW 136
11.2 MALE 139
11.3 FEMALE 139

12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 141

12.1 OVERVIEW 142
12.2 HOSPITALS 145
12.3 ASSOCIATED LABS 145
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 146
12.5 DIAGNOSTIC IMAGING CENTERS 147
12.6 CANCER RESEARCH INSTITUTES 147
12.7 OTHERS 148

13 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150

13.1 OVERVIEW 151
13.2 DIRECT TENDER 154
13.3 RETAIL SALES 154

14 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 156

14.1 EUROPE 157
- 14.1.1 GERMANY 169
- 14.1.2 UNITED KINGDOM 175
- 14.1.3 FRANCE 181
- 14.1.4 ITALY 187
- 14.1.5 SPAIN 193
- 14.1.6 RUSSIA 199
- 14.1.7 NETHERLANDS 205
- 14.1.8 SWITZERLAND 211
- 14.1.9 BELGIUM 217
- 14.1.10 TURKEY 223
- 14.1.11 REST OF EUROPE 229

15 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 230

15.1 COMPANY SHARE ANALYSIS: EUROPE 230

16 SWOT ANALYSIS 231

17 COMPANY PROFILE 232

17.1 CANON MEDICAL SYSTEMS CORPORATION. 232
- 17.1.1 COMPANY SNAPSHOT 232
- 17.1.2 REVENUE ANALYSIS 232
- 17.1.3 COMPANY SHARE ANALYSIS 233
- 17.1.4 PRODUCT PORTFOLIO 233
- 17.1.5 RECENT DEVELOPMENT 233
17.2 SYSMEX CORPORATION 234
- 17.2.1 COMPANY SNAPSHOT 234
- 17.2.2 REVENUE ANALYSIS 234
- 17.2.3 COMPANY SHARE ANALYSIS 235
- 17.2.4 PRODUCT PORTFOLIO 235
- 17.2.5 RECENT DEVELOPMENT 235
17.3 EPIGENOMICS AG. 236
- 17.3.1 COMPANY SNAPSHOT 236
- 17.3.2 REVENUE ANALYSIS 236
- 17.3.3 COMPANY SHARE ANALYSIS 237
- 17.3.4 PRODUCT PORTFOLIO 237
- 17.3.5 RECENT DEVELOPMENT 237
17.4 MYRIAD GENETICS, INC
- 17.4.1 COMPANY SNAPSHOT 238
- 17.4.2 REVENUE ANALYSIS 238
- 17.4.3 COMPANY SHARE ANALYSIS 239
- 17.4.4 PRODUCT PORTFOLIO 239
- 17.4.5 RECENT DEVELOPMENT 239
17.5 F. HOFFMANN- LA ROCHE LTD 240
- 17.5.1 COMPANY SNAPSHOT 240
- 17.5.2 REVENUE ANALYSIS 240
- 17.5.3 COMPANY SHARE ANALYSIS 241
- 17.5.4 PRODUCT PORTFOLIO 241
- 17.5.5 RECENT DEVELOPMENT 241
17.6 ABBOTT 242
- 17.6.1 COMPANY SNAPSHOT 242
- 17.6.2 REVENUE ANALYSIS 242
- 17.6.3 PRODUCT PORTFOLIO 243
- 17.6.4 RECENT DEVELOPMENT 243
17.7 AGILENT TECHNOLOGIES, INC. 244
- 17.7.1 COMPANY SNAPSHOT 244
- 17.7.2 REVENUE ANALYSIS 244
- 17.7.3 PRODUCT PORTFOLIO 245
- 17.7.4 RECENT DEVELOPMENT 245
17.8 BD 246
- 17.8.1 COMPANY SNAPSHOT 246
- 17.8.2 REVENUE ANALYSIS 246
- 17.8.3 PRODUCT PORTFOLIO 247
- 17.8.4 RECENT DEVELOPMENT 247
17.9 BIOMERIEUX 248
- 17.9.1 COMPANY SNAPSHOT 248
- 17.9.2 PRODUCT PORTFOLIO 248
- 17.9.3 RECENT DEVELOPMENT 248
17.10 BIO-RAD LABORATORIES, INC. 249
- 17.10.1 COMPANY SNAPSHOT 249
- 17.10.2 REVENUE ANALYSIS 249
- 17.10.3 PRODUCT PORTFOLIO 250
- 17.10.4 RECENT DEVELOPMENT 250
17.11 DIASORIN S.P.A. 251
- 17.11.1 COMPANY SNAPSHOT 251
- 17.11.2 REVENUE ANALYSIS 251
- 17.11.3 PRODUCT PORTFOLIO 252
- 17.11.4 RECENT DEVELOPMENTS 252
17.12 EXACT SCIENCES CORPORATION 253
- 17.12.1 COMPANY SNAPSHOT 253
- 17.12.2 REVENUE ANALYSIS 253
- 17.12.3 PRODUCT PORTFOLIO 254
- 17.12.4 RECENT DEVELOPMENTS 254
17.13 FONAR CORP. 255
- 17.13.1 COMPANY SNAPSHOT 255
- 17.13.2 REVENUE ANALYSIS 255
- 17.13.3 PRODUCT PORTFOLIO 256
- 17.13.4 RECENT DEVELOPMENT 256
17.14 HOLOGIC INC. 257
- 17.14.1 COMPANY SNAPSHOT 257
- 17.14.2 REVENUE ANALYSIS 257
- 17.14.3 PRODUCT PORTFOLIO 258
- 17.14.4 RECENT DEVELOPMENT 258
17.15 ILLUMINA, INC. 259
- 17.15.1 COMPANY SNAPSHOT 259
- 17.15.2 REVENUE ANALYSIS 259
- 17.15.3 PRODUCT PORTFOLIO 260
- 17.15.4 RECENT DEVELOPMENT 260
17.16 KONINKLIJKE PHILIPS N.V. 261
- 17.16.1 COMPANY SNAPSHOT 261
- 17.16.2 REVENUE ANALYSIS 261
- 17.16.3 PRODUCT PORTFOLIO 262
- 17.16.4 RECENT DEVELOPMENT 262
17.17 MEDONICA CO. LTD 263
- 17.17.1 COMPANY SNAPSHOT 263
- 17.17.2 PRODUCT PORTFOLIO 263
- 17.17.3 RECENT DEVELOPMENT 263
17.18 MERCK KGAA 264
- 17.18.1 COMPANY SNAPSHOT 264
- 17.18.2 REVENUE ANALYSIS 264
- 17.18.3 PRODUCT PORTFOLIO 265
- 17.18.4 RECENT DEVELOPMENTS 265
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 266
- 17.19.1 COMPANY SNAPSHOT 266
- 17.19.2 PRODUCT PORTFOLIO 266
- 17.19.3 RECENT DEVELOPMENT 266

17.20 PLEXBIO 267
- 17.20.1 COMPANY SNAPSHOT 267
- 17.20.2 PRODUCT PORTFOLIO 267
- 17.20.3 RECENT DEVELOPMENTS 267
17.21 QIAGEN 268
- 17.21.1 COMPANY SNAPSHOT 268
- 17.21.2 REVENUE ANALYSIS 268
- 17.21.3 PRODUCT PORTFOLIO 269
- 17.21.4 RECENT DEVELOPMENTS 269
17.22 QUEST DIAGNOSTICS INCORPORATED 270
- 17.22.1 COMPANY SNAPSHOT 270
- 17.22.2 REVENUE ANALYSIS 270
- 17.22.3 PRODUCT PORTFOLIO 271
- 17.22.4 RECENT DEVELOPMENTS 271
17.23 SIEMENS HEALTHCARE GMBH 272
- 17.23.1 COMPANY SNAPSHOT 272
- 17.23.2 REVENUE ANALYSIS 272
- 17.23.3 PRODUCT PORTFOLIO 273
- 17.23.4 RECENT DEVELOPMENT 273
17.24 SONIC HEALTHCARE 274
- 17.24.1 COMPANY SNAPSHOT 274
- 17.24.2 PRODUCT PORTFOLIO 274
- 17.24.3 RECENT DEVELOPMENT 274
17.25 STERNMED GMBH 275
- 17.25.1 COMPANY SNAPSHOT 275
- 17.25.2 PRODUCT PORTFOLIO 275
- 17.25.3 RECENT DEVELOPMENTS 275
17.26 THERMO FISHER SCIENTIFIC INC. 276
- 17.26.1 COMPANY SNAPSHOT 276
- 17.26.2 REVENUE ANALYSIS 276
- 17.26.3 PRODUCT PORTFOLIO 277
- 17.26.4 RECENT DEVELOPMENT 277
17.27 TIME MEDICAL HOLDING 278
- 17.27.1 COMPANY SNAPSHOT 278
- 17.27.2 PRODUCT PORTFOLIO 278
- 17.27.3 RECENT DEVELOPMENT 278

18 QUESTIONNAIRE 279

19 RELATED REPORTS 283

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 64
TABLE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 70
TABLE 3 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 4 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 72
TABLE 5 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 72
TABLE 6 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 7 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 74
TABLE 8 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 9 EUROPE CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 10 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 76
TABLE 11 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77
TABLE 12 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 82
TABLE 13 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 14 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 84
TABLE 15 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 16 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 85
TABLE 17 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 18 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 87
TABLE 19 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 20 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 88
TABLE 21 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 22 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 89
TABLE 23 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 24 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 90
TABLE 25 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 96
TABLE 27 EUROPE MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 28 EUROPE MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 29 EUROPE MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 30 EUROPE PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 31 EUROPE MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 32 EUROPE MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 33 EUROPE ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 34 EUROPE MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 106
TABLE 36 EUROPE 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 37 EUROPE 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 38 EUROPE BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 39 EUROPE 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 114
TABLE 41 EUROPE MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
TABLE 42 EUROPE FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 120
TABLE 44 EUROPE HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 121
TABLE 45 EUROPE ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 46 EUROPE INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 47 EUROPE DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 48 EUROPE CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 49 EUROPE OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
TABLE 50 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 129
TABLE 51 EUROPE DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 130
TABLE 52 EUROPE RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 53 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 138
TABLE 54 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 55 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 138
TABLE 56 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 57 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 58 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 59 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 60 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 61 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 62 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 63 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 64 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 141
TABLE 65 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 66 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 67 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 68 EUROPE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 69 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 143
TABLE 70 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 143
TABLE 71 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 143
TABLE 72 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
TABLE 73 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 144
TABLE 74 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 75 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 76 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 145
TABLE 77 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 78 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 79 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 80 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 81 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 82 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 83 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 147
TABLE 84 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 85 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 86 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 87 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 88 GERMANY GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 89 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 149
TABLE 90 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 149
TABLE 91 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 150
TABLE 92 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 150
TABLE 93 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 150
TABLE 94 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 95 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 96 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 151
TABLE 97 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 98 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 99 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 100 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 101 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 102 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 153
TABLE 103 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 104 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 105 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 106 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 107 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 108 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 109 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 155
TABLE 110 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 156
TABLE 111 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 156
TABLE 112 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 156
TABLE 113 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 156
TABLE 114 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 157
TABLE 115 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 157
TABLE 116 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 157
TABLE 117 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 118 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 119 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 120 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 121 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 122 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 123 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 159
TABLE 124 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 125 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 126 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 127 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 128 FRANCE GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 129 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 161
TABLE 130 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 161
TABLE 131 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 162
TABLE 132 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 162
TABLE 133 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 162
TABLE 134 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 163
TABLE 135 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 163
TABLE 136 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 163
TABLE 137 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 138 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 139 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 140 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 141 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 142 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 165
TABLE 143 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
TABLE 144 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166

LIST OF FIGURES

FIGURE 1 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 34
FIGURE 2 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION 37
FIGURE 3 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS 38
FIGURE 4 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : EUROPE VS REGIONAL MARKET ANALYSIS 39
FIGURE 5 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS 39
FIGURE 6 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS 41
FIGURE 7 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 42
FIGURE 8 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID 44
FIGURE 9 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS 45
FIGURE 10 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 49
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 50
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030 50
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 57
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 59
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 59
FIGURE 16 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 67
FIGURE 17 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 68
FIGURE 18 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 68
FIGURE 19 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 69
FIGURE 20 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022 79
FIGURE 21 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 80
FIGURE 22 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 80
FIGURE 23 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 81
FIGURE 24 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 93
FIGURE 25 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 94
FIGURE 26 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 94
FIGURE 27 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 95
FIGURE 28 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022 103
FIGURE 29 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 104
FIGURE 30 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 104
FIGURE 31 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 105
FIGURE 32 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022 111
FIGURE 33 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 112
FIGURE 34 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 112
FIGURE 35 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 113
FIGURE 36 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022 117
FIGURE 37 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 118
FIGURE 38 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 118
FIGURE 39 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 119
FIGURE 40 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 126
FIGURE 41 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 127
FIGURE 42 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 127
FIGURE 43 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 128
FIGURE 44 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022) 133
FIGURE 45 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022) 135
FIGURE 46 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 135
FIGURE 47 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 136
FIGURE 48 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 136
FIGURE 49 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 205